Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Sari Hernesniemi"'
Autor:
Satu Mustjoki, Sari Hernesniemi, Auvo Rauhala, Marketta Kähkönen, Anders Almqvist, Tuija Lundán, Kimmo Porkka
Publikováno v:
Haematologica, Vol 94, Iss 10 (2009)
Externí odkaz:
https://doaj.org/article/970a97f9b65b44438694ca231c1e2830
Publikováno v:
Leukemia & Lymphoma. 55:934-937
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5359d1210c651c7505301d2e48168f29
https://doi.org/10.3109/10428194.2013.812788
https://doi.org/10.3109/10428194.2013.812788
Autor:
Teresa Melo, Frank Lee, A-M Lahesmaa-Korpinen, Kimmo Porkka, Sari Hernesniemi, Philippe Rousselot, Kaisa Auvinen, Jalkanen S, Anna Kreutzman, Mathieu Molimard, Sampsa Hautaniemi, Satu Mustjoki, Marko Salmi, Jukka Vakkila, Stéphane Bouchet, Richard Smykla
Publikováno v:
Leukemia. 27:914-924
Tyrosine kinase inhibitors (TKIs) have potent effects on malignant cells, and they also target kinases in normal cells, which may have therapeutic implications. Using a collection of 55 leukemia patients treated with TKI therapy (chronic myeloid leuk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de183da18d7541577cec70aacec103f9
https://doi.org/10.1038/leu.2012.348
https://doi.org/10.1038/leu.2012.348
Autor:
Julia Kzhyshkowska, Mari Miiluniemi, Marika Karikoski, Sergij Goerdt, Sari Hernesniemi, Marko Salmi, Kati Elima, Heikki Irjala, Kai Schledzewski, Mikael Maksimow, Kaisa Granfors, Gerhard Moldenhauer, Sirpa Jalkanen
Publikováno v:
European Journal of Immunology. 39:3477-3487
Clever-1/Stabilin-1 is a scavenger receptor present on lymphatic and sinusoidal endothelium as well as on a subset of type II macrophages. It is also induced on vasculature at sites of inflammation. However, its in vivo function has remained practica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ad7ea4e7fd7385da2c6cefcf6f50d0f
https://doi.org/10.1002/eji.200939896
https://doi.org/10.1002/eji.200939896
Autor:
Marika, Karikoski, Heikki, Irjala, Mikael, Maksimow, Mari, Miiluniemi, Kaisa, Granfors, Sari, Hernesniemi, Kati, Elima, Gerhard, Moldenhauer, Kai, Schledzewski, Julia, Kzhyshkowska, Sergij, Goerdt, Marko, Salmi, Sirpa, Jalkanen
Publikováno v:
European journal of immunology. 39(12)
Clever-1/Stabilin-1 is a scavenger receptor present on lymphatic and sinusoidal endothelium as well as on a subset of type II macrophages. It is also induced on vasculature at sites of inflammation. However, its in vivo function has remained practica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1040d709e4b0fdcfcf2297bf77c33103
https://pubmed.ncbi.nlm.nih.gov/19830743
https://pubmed.ncbi.nlm.nih.gov/19830743
Autor:
Anders Almqvist, Satu Mustjoki, Auvo Rauhala, Sari Hernesniemi, Tuija Lundán, Kimmo Porkka, Marketta Kähkönen
Dasatinib, a wide-spectrum tyrosine kinase inhibitor (TKI), has shown notable clinical activity in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) patients carrying a 9;22 translocation and the resulting BCR-ABL1 fusion gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da09bbbd3c8c23d6dac1959d3ae782c1
https://europepmc.org/articles/PMC2754971/
https://europepmc.org/articles/PMC2754971/
Publikováno v:
Blood. 112:4214-4214
Aberrant cytokine and growth factor signaling is the hallmark of CML and results from constitutive oligomerization of the oncogenic BCR-ABL tyrosine kinase (TK). Inhibition of BCR-ABL by imatinib mesylate is the current standard of care of CML and re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f79b32efcd89ce5269d70fef7c877042
https://doi.org/10.1182/blood.v112.11.4214.4214
https://doi.org/10.1182/blood.v112.11.4214.4214
Autor:
Katrin Rapakko, Satu Mustjoki, Perttu Koskenvesa, Sari Hernesniemi, Tuija Lundán, Peter Rohon, Kimmo Porkka
Publikováno v:
Blood. 112:1079-1079
Targeted tyrosine kinase inhibitors (TKIs) efficiently induce rapid hematologic and cytogenetic remission in most chronic myeloid leukemia (CML) patients. However, in vitro experiments have suggested that the most primitive CML stem cells residing in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3349548bb8427b58c528098300f2e5cb
https://doi.org/10.1182/blood.v112.11.1079.1079
https://doi.org/10.1182/blood.v112.11.1079.1079
Autor:
Satu Mustjoki, Marja Ekblom, Kimmo Porkka, Ronald Paquette, Javier Pinilla, Ingunn Dybedal, Tobias Gedde-Dahl, Marjatta Sinisalo, Bengt Simonsson, Tuisku Laurinolli, Vesa Juvonen, Martin Höglund, Juan Luis Steegmann, Sari Hernesniemi, Jane L. Liesveld, Felix T. Garzon, Pearlie K. Epling-Burnette, Panu E. Kovanen, Anna Kreutzman, Neil P. Shah, T. Petteri Arstila, Auvo Rauhala, Leif Stenke, Veli Kairisto, Henrik Hjorth-Hansen, Jukka Vakkila
Publikováno v:
Blood. 112:573-573
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL fusion protein are an effective therapy for Philadelphia chromosome positive (Ph+) leukemia. Dasatinib, a 2nd generation pan-TKI, also inhibits wild-type kinases, which may result in unexpected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97ef1c4fe0454e0a4430a73a89acec9d
https://doi.org/10.1182/blood.v112.11.573.573
https://doi.org/10.1182/blood.v112.11.573.573